More oesophageal cancer patients benefit from pre-op chemo than previously thought says study

December 23, 2013

More oesophageal cancer patients than previously thought are benefiting from having chemotherapy before an operation to remove their tumour, according to new research published in the World Journal of Gastroenterology.

And, for these patients, this could mean an increased chance of survival or lengthening the time before their cancer returns. 

Researchers from the University of Southampton looked at the records of over 200 patients with a type of known as adenocarcinoma treated at Southampton General Hospital.

Previous research has shown that giving before surgery can benefit some patients by causing their tumours to shrink.

But in addition to these patients, the researchers found that an extra group also benefitted from the chemotherapy. Even though it had not shrunk the original tumour, it did reduce the spread of the disease in the . And this had a knock on effect of better survival and longer time between relapses.

The clinicians also believe that another course of chemotherapy after surgery could benefit these patients even more. 

In the study, over a quarter of patients (26 per cent; 36 patients) who had chemotherapy before surgery had tumours that responded significantly to the treatment compared to 74 per cent (100 patients) whose tumours did not respond. 

But 30 additional patients also benefitted from the chemotherapy as they had a reduction in the number of lymph nodes with cancer in them. In this group the average time to relapse of the cancer was increased from just over one year to more than five and a half years.

The study was funded by Cancer Research UK and the Medical Research Council (MRC). 

Mr Tim Underwood, an MRC Clinician Scientist, oesophageal surgeon researcher at The University of Southampton and one of the study authors, said: "We still don't know why some patients respond to chemotherapy, and others don't. But this study suggests that more patients than previously thought do benefit from chemotherapy before surgery, which means that having more treatment after their operation might also work for them too.

"We're at the start of the journey to find markers that will help us tailor our treatments for patients with oesophageal cancer. There's so much more we need to find out about this form of cancer – which is why I'm working on one of the most important research projects to unravel the genetic code of oesophageal cancer. British scientists, funded by Cancer Research UK's Catalyst Club, are working on this as part of the International Cancer Genome Consortium (ICGC)."

Oesophageal cancer is the ninth most common cancer in the UK with around 8,500 new cases diagnosed in the UK every year. It is also the sixth most common cause of cancer death. It is more common in people who smoke, drink alcohol, are overweight and eat little fresh fruit and vegetables. 

Kate Law, Cancer Research UK's director of clinical trials, said: "This study is another piece in the jigsaw in helping us to understand how to tailor treatment to the type of cancer that oesophageal have.

"The number of cases of oesophageal cancer are on the increase, but survival still remains poor. This is why Cancer Research UK is making oesophageal a research priority in order to make headway in the fight against this devastating disease."

Explore further: Re-thinking cancer treatment

More information: Noble, F et al. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus (2013) World Journal of GastroenterologyDOI: 10.3748/wjg.v19.i47.0000

Related Stories

Re-thinking cancer treatment

November 18, 2013
A new treatment approach for tackling cancer of the food pipe (oesophagus) has been developed by researchers at Cardiff and Velindre NHS Trust.

A quiet epidemic: Men's risk of oesophageal cancer is triple women's risk

June 18, 2013
(Medical Xpress)—Men are almost three times more likely to get oesophageal cancer than women – one of the biggest gender gaps in cancer rates – according to figures released from Cancer Research UK.

China study shows fibre for oesophageal cancer prevention

November 21, 2013
Populations in China's north-west have been the focus of research which investigated risk factors for oesophageal cancer.

New drug extends life in women with advanced ovarian cancer

November 5, 2013
Women with ovarian cancer that has returned after previous treatment had their life extended by almost three months after treatment with a drug called Cediranib, according to trial results presented today at the National ...

Centralization to fewer surgeons results in better survival after esophageal cancer surgery

January 7, 2013
Patients who undergo surgery for oesophageal cancer have a much greater chance of long term survival if the operation is carried out by a surgeon who has performed this particular operation many times before. This according ...

New research shows 'DNA tags' could guide treatment for advanced ovarian cancer

October 15, 2013
A Cancer Research UK study has identified chemical 'tags' on DNA in patients' tumours that could help doctors decide the type of chemotherapy women with advanced ovarian cancer should receive, according to a new paper published ...

Recommended for you

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.